Rivulobirin B is primarily investigated for its potential antitumor and cytotoxic properties. It has shown activity in inhibiting the growth of certain cancer cell lines, making it a subject of interest in oncology research. Its mechanism appears to involve interference with cellular proliferation pathways, although the exact target is still under study. Due to its natural origin and complex structure, it also serves as a lead compound in the development of novel chemotherapeutic agents. Research applications include use in laboratory studies to understand apoptosis induction and cell cycle regulation in malignant cells. Its application remains mostly confined to preclinical research due to limited availability and the need for further pharmacological evaluation.